Retatrutide triple hormone receptor agonist for obesity
New England Journal of Medicine
2023
Study summary
Retatrutide investigated as GLP-1/GIP/glucagon receptor agonist for obesity treatment.
Peptides studied
Goals studied
Stack studied
Advanced Metabolic Stack
Key findings
Marked reductions in body weight were reported in phase 2 trials.
Study details
Study type
phase 2 clinical trial
Journal
New England Journal of Medicine
DOI / PubMed
10.1056/NEJMoa2301972
Year
2023
Explore peptide profiles
Discover compounds, understand their mechanisms, and explore the research behind each peptide.
